A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG/ Alliance Z5041 Trial
   Google Scholar   
Citation:
J Clin Oncol vol 36 (15_suppl) 4112
Meeting Instance:
ASCO 2018
Year:
2018
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3037  
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                                       
Networks:
11030, FL028, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NY016, LAPS-TN008, LAPS-TX035, LAPS-WI013, NORTHWELL   
Study
ACOSOG-Z5041
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: